Rise and shine, everyone, another busy day is on the way. We can tell, in part, because our short person is hunched over a lap top for another round of remote learning and our official mascot is ceaselessly bounding about the grounds in search of squirrels and chipmunks. As for us, we are brewing cups of stimulation and foraging for items of interest, a never-ending process. Speaking of which, here are a few tidbits to help you along. As always, we hope your day is productive and enjoyable. Stay in touch and stay safe. …

The White House cast aside its objections and endorsed Food and Drug Administration plans for assessing whether a Covid-19 vaccine should be given to the public, making it likely that a shot will not be cleared until after the election, The Wall Street Journal reports. The FDA issued the guidelines soon afterward on Tuesday afternoon. The guidelines call for a two-month observation period to see whether people who got the vaccine had suffered negative side effects.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy